Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132507) titled 'Population Pharmacokinetic Modeling and Dosing Optimization of Eravacycline in Critically Ill Patients with Severe Pneumonia' on Sept. 15.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Tianjin First Central Hospital

Condition: Severe Pneumonia

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2026-04-29

Target Sample Size: Intravenous eravacycline group:50;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=341170

Published by HT Digital Content Services with permission from Health Daily Digest....